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Abstract 
Background: Acute kidney injury (AKI) in the intensive care unit is associated with significant mortality and 
morbidity.
Objectives: To determine and update previous recommendations for the prevention of AKI, specifically the role of 
fluids, diuretics, inotropes, vasopressors/vasodilators, hormonal and nutritional interventions, sedatives, statins, remote 
ischaemic preconditioning and care bundles.
Method: A systematic search of the literature was performed for studies published between 1966 and March 2017 
using these potential protective strategies in adult patients at risk of AKI. The following clinical conditions were 
considered: major surgery, critical illness, sepsis, shock, exposure to potentially nephrotoxic drugs and radiocontrast. 
Clinical endpoints included incidence or grade of AKI, the need for renal replacement therapy and mortality. Studies 
were graded according to the international GRADE system.
Results: We formulated 12 recommendations, 13 suggestions and seven best practice statements. The few strong 
recommendations with high‑level evidence are mostly against the intervention in question (starches, low‑dose dopa‑
mine, statins in cardiac surgery). Strong recommendations with lower‑level evidence include controlled fluid resusci‑
tation with crystalloids, avoiding fluid overload, titration of norepinephrine to a target MAP of 65–70 mmHg (unless 
chronic hypertension) and not using diuretics or levosimendan for kidney protection solely.
Conclusion: The results of recent randomised controlled trials have allowed the formulation of new recommenda‑
tions and/or increase the strength of previous recommendations. On the other hand, in many domains the available 
evidence remains insufficient, resulting from the limited quality of the clinical trials and the poor reporting of kidney 
outcomes.
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Professor Groeneveld succumbed to a long illness which he fought with 
typical determination during the updating of this paper. He is sadly 
missed by us all.
Introduction
Acute kidney injury (AKI) affects up to 50% of critically ill 
patients and is independently associated with both short- 
and long-term morbidity and mortality [1–5]. The recent 
AKI-EPI study demonstrates that the most frequent 
causes of AKI in the critically ill are sepsis and hypovol-
aemia followed by nephrotoxic agents [6]. However, the 
cause of AKI is often multifactorial with pre-existing co-
morbidities further increasing the risk [3, 7–9].
The aim of this systematic review on the prevention 
and avoidance of further progression of AKI, by core 
members of the AKI section of the ESICM, is to provide:
  • A critical evaluation of the existing evidence
  • Give recommendations for clinical practice
  • Update our previously published recommendations 
[10] and most recent guidelines [2, 11]
Our recommendations principally concern critically 
ill patients on the ICU but can also be applied to those 
planned to be admitted to the ICU such as high-risk sur-
gical patients. By consensus, we primarily focussed on 
the role of volume expansion, diuretics, inotropes, vaso-
pressors/vasodilators, hormones, nutrition, statins, seda-
tives and ischaemic preconditioning.
Methodology
A systematic search of the literature was performed 
using the following databases: MEDLINE (1966 
through March 2017), EMBASE (1980 through March 
2017), CINAHL (1982 through March 2017), Web of 
Science (1955 through March 2017) and PubMed/
PubMed CENTRAL to identify key studies, prefer-
ably randomised (placebo) controlled trials (RCT) and 
meta-analyses, addressing strategies to prevent AKI in 
adult critically ill patients. The following clinical con-
ditions were considered: major surgery, critical illness, 
sepsis, shock and exposure to potentially nephrotoxic 
drugs. Specifically, renal transplantation, primary 
intrinsic renal disease (e.g. vasculitis) and hepatorenal 
syndrome were not considered. Search strategy and 
endpoints are available as electronic supplementary 
material (ESM_1).
These recommendations are intended to provide clini-
cal guidance and involved a modified Delphi process with 
a consensus meeting during the annual congresses of the 
European Society of Intensive Care Medicine in 2014, 
2015 and 2016 followed by electronic-based/telephone 
discussions. The quality of the evidence was judged by 
using the most recent GRADE (Gradings of Recommen-
dations, Assessment, Development and Evaluation) crite-
ria (Fig. 1) [12, 13]. The strength of the recommendations 
was classified as either strong (Grade 1) or weak (Grade 
2). The degree (i.e. quality) of evidence for the recom-
mendations was classified from high (A) to very low (D) 
according to factors including study design consistency of 
the results and directness of the evidence (Fig. 1, ESM_1 
Table  S1). Evidence was downgraded where there was a 
risk of bias, inconsistency and imprecision. Evidence was 
upgraded for large effect size or significant dose–response 
gradient. If benefit or harm was unequivocal, but evidence 
was difficult to categorize by the GRADE methodology, 
we used best practice statements (BPSs), which represent 
ungraded strong recommendations [14] (Table 1).
We acknowledge that there may be circumstances 
whereby a recommendation cannot or should not be fol-
lowed for an individual patient. Furthermore, interven-
tions are generally investigated in isolation and not in 
combination, and as such recommendations relate to the 
primary intervention. Local clinical guidelines will gov-
ern the use of either a single intervention or a combina-
tion thereof.
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Fig. 1 Grade system for grading recommendations (Modified from 
Guyatt et al. [12])
Table 1 Criteria for  best practice statements (Modified 
from Guyatt et al. [14])
GRADE Gradings of Recommendations, Assessment, Development, and 
Evaluation
Criteria for best practice statements
1 Is the statement clear and actionable?
2 Is the message necessary?
3 Is the net benefit (or harm) unequivocal?
4 Is the evidence difficult to collect and summarize?
5 Is the rationale explicit?
6 Is this better to be formally GRADEd?
Volume expansion
Recommendations
1. We recommend controlled fluid resuscitation in vol-
ume depletion, while, however, avoiding volume 
overload (Grade 1C).
2. We recommend against the use of starches (Grade 
1A) as harm has been shown and suggest not using 
gelatine or dextrans for fluid resuscitation (Grade 
2C).
3. We recommend correction of hypovolaemia/dehy-
dration using isotonic crystalloids in patients receiv-
ing intravascular contrast media (Grade 1B).
4. We recommend regular monitoring of chloride levels 
and acid–base status in  situations where chloride-
rich solutions are used (BPS).
5. We suggest the use of balanced crystalloids for large 
volume resuscitation (Grade 2C).
6. We suggest using human serum albumin if a colloid is 
deemed necessary for the treatment of patients with 
septic shock (Grade 2C).
7. We suggest prophylactic volume expansion with crys-
talloids to prevent AKI by certain drugs (specified 
below) (BPS).
8. We suggest not delaying urgent contrast-enhanced 
investigations or interventions for potential preven-
tative measures (BPS).
Rationale
Relative and overt hypovolaemia are significant risk factors 
for development of AKI [15–18]. Timely fluid administra-
tion can restore circulating volume and renal perfusion, 
and may also reduce nephrotoxicity [19]. Volume replace-
ment should be performed in a controlled, monitored fash-
ion [20] as injudicious use of fluids carries its own inherent 
risks and may even contribute to AKI by increasing renal 
interstitial oedema and renal parenchymal pressure [21, 
22]. Moreover, goal-directed therapy including the use 
of central venous pressure (CVP) as a resuscitation target 
has not been shown to prevent AKI in sepsis [23]. Volume 
replacement may be through crystalloids, colloids or their 
combination. Isotonic crystalloids represent the main-
stay for correcting extracellular volume depletion with the 
caveat that hyperchloraemia is prevented to reduce poten-
tial renal vasoconstriction [24, 25]. Compared to crys-
talloids, colloids theoretically result in a greater plasma 
expansion. However, this effect depends on vascular barrier 
integrity which may be compromised in sepsis, particularly 
in the presence of vasoplegia [26, 27]. Consequently, the 
difference in required volumes for fluid resuscitation was 
minimal between crystalloids and colloids in large RCTs 
[28]. Moreover, large volume replacement with colloids 
alone risks hyperoncotic impairment of glomerular filtra-
tion [29, 30] and osmotic tubular damage [31, 32].
Available artificial colloids include gelatines, dextrans 
and until recently, starches. Gelatines have a moderate 
volume effect. Although risk of osmotic nephrosis with 
gelatines exists [33], the lack of clear clinical data on 
deleterious effects on renal function [34, 35] is offset by 
the possible prion transmission, histamine release and 
coagulopathy [36, 37]. Dextrans have reasonably high 
volume effects although anaphylaxis, coagulation disor-
ders, osmotic nephrosis and AKI may occur with doses 
above 1.5 g/kg/day [38–41]. Human albumin (HA) is the 
only naturally occurring colloid and may appear attrac-
tive in hypooncotic hypovolaemia. It does increase the 
response to diuretics in patients with hypoalbuminaemia 
(e.g. nephrotic syndrome) [42, 43], has no negative effects 
on kidney function [44, 45], is safe [46] but can be costly.
Clinical studies
Unsurprisingly, no studies have specifically addressed 
the effects of volume expansion compared to no volume 
resuscitation in overt hypovolaemia given the intui-
tive benefits of volume replacement. In severe sepsis, 
the beneficial effects of timely volume replacement on 
organ failure and mortality are well known, although the 
first RCT proving benefit of early volume resuscitation 
did not report kidney function [47]. On the other hand, 
preoperative volume expansion failed to reduce the inci-
dence of postoperative AKI ins 328 patients undergoing 
cardiac surgery [48], and a recent pilot RCT in sepsis 
could demonstrate that a volume-restrictive fluid proto-
col can reduced the incidence of AKI (RR 0.32; 95% CI 
0.32–0.96) [49].
Crystalloids are considered the mainstay for volume 
expansion. Observational studies suggest an increased 
risk of AKI, renal replacement therapy (RRT) and 
mortality associated with the use of large volumes of 
normal saline (0.9% NaCl) as compared to so-called 
balanced solutions where chloride is partially replaced 
by another metabolizable anion [50–52]. An RCT 
comparing saline to a balanced solution  (Plasmalyte®) 
in 2278 patients treated in four ICUs failed to show 
any superiority of balanced crystalloids regarding 
renal outcomes [53]. The study has been criticized for 
the limited fluid doses, inclusion of patients with low 
disease severity and the absence of data on chloride 
levels [54]. Similar results were observed in the pilot 
cluster-randomised, multiple-crossover SALT trial 
comparing saline to a balanced solution in 974 criti-
cally ill adults [55]. Again, only modest volumes were 
used, but increased rates of AKI were found in the 
normal saline group if larger volumes were adminis-
tered (ESM_2 Table S2). Studies on the effectiveness of 
sodium bicarbonate in preventing AKI, predominantly 
in patients undergoing cardiac surgery, have produced 
conflicting results [56–59] as have consecutive meta-
analyses [60–63].
The effect of colloids on renal function has undergone 
extensive scrutiny over the last decade. Large RCTs have 
substantiated the increased risk of AKI and RRT with use 
of starches [64] particularly in sepsis [65, 66], where they 
also lead to increased mortality [66] (ESM_2 Table  S3). 
This is verified by several meta-analyses [67–70] which 
underpin the abandoning of starches in critically ill 
patients [20, 71, 72]. Clinical data on the effects of gela-
tine on renal function are scarce. A recent meta-analysis, 
including three trials in 212 patients comparing gelatins 
with crystalloids or albumin, indicated a 35% increased 
relative risk of developing AKI with gelatine [73].
In contrast to artificial colloids, the administration of 
albumin appears to be safe for the kidney. A large RCT 
comparing normal saline to 4% HA in various clinical set-
tings failed to demonstrate any differences in renal func-
tion [46] (ESM_2 Table S3). In the ALBIOS trial the use 
of hyperoncotic (20%) albumin showed no effect on AKI 
or need for RRT in severe sepsis [74] but enabled a less 
positive fluid balance, confirming the results of another 
small trial [75]. A post hoc analysis of the ALBIOS trial 
showed survival benefit in septic shock [74] confirmed 
by meta-analyses [76, 77]. Hypoalbuminaemia in cardiac 
surgery might be another indication with improved fluid 
balance as well as a reduced rate of AKI being observed 
in a single-centre RCT of 220 patients [78].
Hypovolaemia may also contribute significantly towards 
drug-induced renal injury, although the available evidence 
supporting preventative hydration is only observational 
with no consensus related to timing, optimal volume 
and type of solution [19, 79, 80]. Prophylactic volume 
expansion has been shown to prevent harm from ampho-
tericin B, antivirals including foscarnet, cidofovir and ade-
fovir [81–83] as well as drugs causing crystal nephropathy 
such as indinavir, acyclovir, and sulfadiazine [84].
Prophylactic volume expansion is the mainstay of all 
recommendations to prevent contrast-associated AKI 
(CA-AKI) and is based on several randomised controlled 
studies performed in non-critically ill patients [85–90]. 
However, studies comparing hydration to no hydration 
are scarce [91]. Several pitfalls should be considered. 
First, CA-AKI is a diagnosis of exclusion and consider-
able variation exists with regard to the reported inci-
dence rates, which are confounded by many factors such 
as transient fluctuations in measured serum creatinine in 
hospitalised patients and use of non-standardised diag-
nostic criteria [92]. Secondly, CA-AKI does not occur in 
patients without other risk factors for AKI, whereas most 
critically ill patients receiving intravascular contrast have 
other risk factors. Moreover, individuals with high risk 
for CA-AKI may not be given contrast. For these reasons 
the role of CA-AKI is uncertain, particularly in an era 
where the use of low- or iso-osmotic agents and lower 
contrast volume administration have become standard 
practice. As indicated by an analysis of the Nationwide 
Inpatient Sample dataset comprising 5, 931,523 hos-
pitalisations the OR for CA-AKI adjusted for age, sex, 
mechanical ventilation and combined co-morbidity score 
was 0.93 (0.88–0.97) [93]. Whereas a retrospective single-
centre cohort study in 747 critically ill patients showed 
a rate of CA-AKI of 16% [94], matched cohort studies 
could not demonstrate a relationship with IV contrast 
for computed tomography in the ICU [95–97] or emer-
gency department [98]. These findings are supported by 
a systematic review and Bayesian meta-analysis [99]. In 
the most recent propensity-matched cohort study, IV 
contrast was not associated with an increased risk of AKI 
or dialysis, but a subgroup with pre-CT eGFR of at most 
45 ml/min/1.73 m2 showed an increased risk of dialysis. 
The numbers in this subgroup were, however, small and 
subject to selection bias [97].
Although it seems prudent to correct hypovolaemia 
before contrast administration, prophylactic volume 
expansion in critically ll patients who are euvolaemic 
cannot be recommended on the basis of current data. No 
study demonstrates protection of pre-emptive volume 
expansion against CA-AKI in the critically ill. An RCT 
comparing hydration with isotonic bicarbonate versus 
normal saline failed to show superiority of either regimen 
but reported an excessively high rate of CA-AKI of 33% 
in both groups [100], which may be attributed to sever-
ity of illness in this critically ill cohort. Importantly, in 
patients with chronic kidney disease (CKD) undergoing 
percutaneous coronary intervention (PCI), hydration vol-
umes above 11 ml/kg body weight (BW) were associated 
with continuously increased rates of AKI, requirement 
for RRT and mortality. The adjusted OR for develop-
ing AKI with hydration volumes greater than 25  ml/kg 
BW was 2.11 (CI 1.24–3.59) [101]. We recommend that 
the clinical decision to perform a contrast study in ICU 
patients must weigh the potential benefits with the low 
but probably not zero risk of CA-AKI.
Diuretics
Recommendations
1. We recommend against loop diuretics given solely for 
the prevention of acute kidney injury (Grade 1B).
2. We suggest using diuretics to control or avoid fluid 
overload in patients that are diuretic-responsive 
(Grade 2D).
Rationale
Oligoanuria is frequently the first indicator of acute renal 
dysfunction. Intensivists frequently use loop diuretics in 
a wide spectrum of AKI settings [102]. The rationale for 
using diuretics to ameliorate AKI includes prevention 
of tubular obstruction, reduction in medullary oxygen 
consumption and increase in renal blood flow as well as 
reducing fluid overload and venous congestion [103–
105]. Although there is no single parameter for fluid 
overload, increased CVP [106], peripheral oedema [107] 
and/or increased intra-abdominal pressure [108, 109] 
may be used as surrogates. A recent study demonstrated 
than a urinary output of at least 100 ml/h following a test 
dose of 1.0–1.5 mg furosemide/kg BW predicted reduced 
progression to a higher stage of AKI in oliguric patients 
[110].
Clinical studies
Use of conservative fluid management including diuretics 
has been investigated in only one large RCT in patients 
with acute lung injury (FACTT trial) which showed a 
tendency to reduced requirement of RRT [111].
In cardiac surgery either no protection [112] or ele-
vated postoperative serum creatinine levels were found in 
patients receiving furosemide [113]. These findings were 
supported by a recent meta-analysis [114]. In patients 
with acute heart failure, diuretic therapy with higher 
doses was more effective at reducing clinical symp-
toms, but at the cost of decreased renal function [115]. 
To date four RCTs have examined the role of diuretics in 
established renal failure in the intensive care setting. No 
demonstrable improvements in clinically relevant out-
comes, such as recovery of renal function or mortality, 
were observed [31, 116–118]. Other studies compared 
diuretics with dopamine or placebo, again with no per-
ceived benefit [119–121]. Three meta-analyses confirmed 
that the use of diuretics in established AKI did not alter 
outcome but carried a significant risk of side effects such 
as hearing loss [122–124] (ESM_2 Table S4).
Vasopressors
Recommendations
1. We recommend titrating vasopressors to a mean arte-
rial pressure (MAP) of 65–70  mmHg (Grade 1B) 
rather than a higher MAP target (80–85  mmHg) in 
patients with septic shock. However, for patients 
with chronic hypertension we recommend aiming for 
a higher target (80–85 mmHg) for renal protection in 
septic shock (Grade 1C).
2. We recommend lowering systolic pressure to 
140–190  mmHg rather than to 110–139  mmHg in 
patients with acute cerebral haemorrhage with severe 
admission hypertension (Grade 1C).
3. If vasopressors are needed for treatment of hypoten-
sion, we recommend norepinephrine (along with cor-
rection of hypovolaemia) as the first-choice vasopres-
sor to protect kidney function (Grade 1B) and suggest 
vasopressin in patients with vasoplegic shock after 
cardiac surgery (Grade 2C).
4. We suggest individualizing target pressure when pre-
morbid blood pressure is available (BPS).
Rationale for MAP target
Preservation or improvement of renal perfusion can 
theoretically be achieved through increasing cardiac 
output by fluid resuscitation or inotropic drugs, through 
renal vasodilators or systemic vasopressors. Optimal tar-
get mean arterial pressure (MAP) was studied in a large 
open-label multicentre RCT randomising 777 patients 
with septic shock to resuscitation with a MAP target of 
either 80–85  mmHg or 65–70  mmHg [125]. In most of 
the patients the achieved MAP was above the set target. 
The study found no difference in mortality, incidence of 
AKI stage 2 (38.7% vs. 41.5%, p = 0.42) or need for RRT 
(33.5% vs. 35.8%, p = 0.5), but more atrial fibrillation in 
the high target group. However, in patients with known 
chronic hypertension a higher MAP resulted in a lower 
incidence of AKI stage 2 (38.9% vs. 52%, p =  0.02) and 
less RRT (31.7% vs 42.2%, p  =  0.046); mortality was 
unchanged.
The safety of lowering systolic pressure was studied in 
a larger RCT in patients with acute cerebral haemorrhage 
with severe hypertension on admission [126]. Patients 
were randomised to a systolic blood pressure target of 
110–139 or 140–179  mmHg. The primary endpoint 
(death or disability) was not different between groups. 
However, the rate of serious renal adverse events was 
higher in the lower target group (9% vs. 4%, p =  0.002) 
(ESM_2 Table S5).
Rationale for choice of vasopressor
Norepinephrine is the most commonly used vasopressor 
in patients with vasodilatory shock. A large RCT com-
paring dopamine to norepinephrine as initial vasopressor 
in patients with shock found no difference in mortality 
between randomised groups. However, norepinephrine 
was associated with less tachycardia in the first hours 
and was superior regarding survival in cardiogenic shock 
patients. In addition, there was a trend towards more 
RRT-free days through day 28 in the norepinephrine 
group [127].
Vasopressin or the analogue terlipressin may have a 
role in the treatment of norepinephrine-refractory shock 
[128]. Exogenous vasopressin has vasoconstrictive and 
antidiuretic properties and may increase glomerular fil-
tration by preferential post-glomerular vasoconstriction 
[129]. In the largest RCT in septic shock (VASST trial), 
vasopressin reduced mortality in the subgroup with less 
severe shock, but not in the entire population. There were 
no differences in RRT-free days [130]. However, in a sec-
ondary analysis, a reduced progression to higher stages of 
AKI could be demonstrated in the subgroup of patients 
with AKI stage 1 at baseline [131]. In a subsequent 2 × 2 
RCT in 409 patients with early septic shock (VANISH 
trial) [132], the use of vasopressin compared to norepi-
nephrine did not affect the proportion of patients who 
never developed AKI stage 3 (57% vs. 59.2%), the num-
ber of AKI stage  3-free days [difference −4 (−11 to 5)] 
or the incidence of AKI stage 3 [difference −5.1% (−15.2 
to 5.0)]. The use of vasopressin reduced the need for 
RRT (difference −9.9% (−19.3 to −0.6), but only in non-
survivors. A recent single-centre RCT in 300 patients 
with vasoplegic shock after cardiac surgery compared 
noradrenalin to vasopressin as first-choice vasopressor. 
The use of vasopressin was associated with less acute 
renal failure (10.3% vs. 35.8%, p < 0.0001) and less RRT 
(2.7% vs. 13.9%, p  =  0.0016) [133]. This trial, however, 
had some design issues (e.g. change in primary outcome 
during the study) and requires confirmation. The studies 
are summarized in ESM_2 Table S5.
Use of vasodilators
Recommendations
1. We recommend against low-dose dopamine for pro-
tection against AKI (Grade 1A).
2. We recommend not using levosimendan for renal 
protection in patients with sepsis (Grade 1B) and 
recommend against its use for renal protection in car-
diac surgery patients with poor preoperative left ven-
tricular function or needing postoperative haemody-
namic support (Grade 1B).
3. We suggest not using fenoldopam or natriuretic pep-
tides for renal protection in critically ill or cardiovas-
cular surgery patients at risk of AKI (Grade 2B).
Rationale
Early in the course of ischaemic AKI, renal blood flow 
(RBF) falls because of stimulation of the sympathetic 
nervous system and the release of vasoconstrictors such 
as endothelin, angiotensin II and vasoconstrictive prosta-
glandins [134, 135]. In contrast, during septic AKI global 
RBF seems to be well preserved [136, 137]. The main 
perfusion problem during sepsis seems to occur at the 
microvascular level and regionally in the outer medulla 
[138]. When using vasodilators for kidney protection, 
several issues should be considered. First, vasodilators 
may cause hypotension by counteracting compensatory 
vasoconstriction, thus unmasking occult hypovolaemia. 
Hypotension may further compromise renal perfusion 
and correction of hypovolaemia is therefore crucial. Sec-
ond, as a result of endothelial damage, nitric oxide (NO)-
dependent vasodilators seem to be ineffective [135]. 
Third, timing may be crucial, since delayed administra-
tion reduces effectiveness as a result of occlusion of the 
microcirculation [139].
Clinical studies
Low-dose  or ‘renal’ dose dopamine  has been advocated 
in the past to prevent selective renal vasoconstriction in 
a variety of conditions. This may not be the case in com-
plex clinical conditions, where low-dose dopamine may 
even worsen renal perfusion [140]. Several meta-analyses 
have concluded that ‘renal-dose’ dopamine has no benefit 
in either preventing or ameliorating AKI in the critically 
ill [141–143], the latest [141] being presented in ESM_2 
Table S6.
Fenoldopam is a pure dopamine-A1 receptor agonist 
providing systemic and renal vasodilation and natriu-
resis, and it has been studied in cardiovascular surgery 
and critically ill patients. Two older meta-analyses, one 
including 1290 critically ill and surgical patients (mainly 
cardiovascular) from 16 RCTs and the other including 
1059 cardiac surgery patients from 13 (partially overlap-
ping) RCTs and case-matched studies, reported that the 
use of fenoldopam reduced the incidence of AKI, need 
for RRT and hospital mortality [144]. Most studies were 
small with a moderate to high risk of bias and in the 
second meta-analysis 30% of the included studies were 
abstracts. The two most recent meta-analyses in cardiac 
surgery and major surgery used stricter inclusion criteria 
[145, 146] and only found a lower risk for AKI, but not 
for RRT or death. In addition, both showed an increased 
risk of hypotension and most included studies had a high 
risk of bias due to low sample size and fragility index, and 
use of different definitions for AKI. The most recent and 
largest RCT in post cardiac surgery patients with AKIN 
stage I [147] did not show any renal protection or clinical 
benefit from the use of fenoldopam, while fenoldopam 
conferred more hypotension. (Studies are summarized in 
ESM_2 Table S7).
Atrial natriuretic peptide (ANP) is produced by car-
diac atria in response to an acute increase in stretch and/
or pressure and induces afferent dilatation and efferent 
vasoconstriction, thereby increasing glomerular filtration 
and urinary sodium excretion with a dose-dependent 
hypotensive effect [148, 149]. B-type (brain) natriuretic 
peptide (BNP) is primarily produced in the cardiac ven-
tricles and has similar effects [150, 151].
The two most recent meta-analyses including RCTs in 
the cardiac and cardiovascular surgery population found 
that the prophylactic infusion of low-dose ANP reduced 
postoperative peak creatinine [152] and the need for RRT 
[152–154]. However, the latter was based on only 24 cases 
of RRT in 563 patients. No effect was found in estab-
lished AKI and high-dose ANP was associated with more 
frequent adverse effects (arrhythmias, hypotension) [154]. 
Two later RCTs on the use of ANP in aortic arch (n = 42) 
and high-risk cardiac surgery (n  =  367) confirmed a 
reduction in postoperative AKI and need for RRT (0/183 
vs. 7/184, p = 0.015) [155, 156] (ESM_2 Table S8).
A recent meta-analysis including 15 RCTs in 9623 
patients with acute decompensated heart failure showed 
that the use of BNP (nesiritide) was associated with wors-
ening renal function: RR 1.08 (1.01–1.15), especially in 
the subgroup receiving a high dose (>0.01  μg/kg/min) 
and in patients without CKD [157].
In general, most BNP trials were small, not powered for 
the endpoints RRT or mortality, of poor quality with low 
fragility index; inclusion criteria varied and results were 
heterogeneous. Furthermore, hypotension and arrhyth-
mia were frequently reported. A small subgroup meta-
analysis on BNP in cardiovascular surgery also showed 
no benefit [152] (ESM_2 Table S8).
The calcium sensitizer levosimendan has inodilator, 
cardioprotective and anti-inflammatory effects [158, 
159]. In a recent meta-analysis of RCTs in the cardiac 
surgery population (13 trials, 1345 patients), the use of 
levosimendan decreased the risk of AKI [OR 0.51 (0.24–
0.79)], the need for RRT [OR 0.43 (0.25–0.76)] and mor-
tality [OR 0.41 (0.27–0.62)] [160]. The last meta-analysis 
of RCTs in the critically ill population with or at risk of 
AKI (33 RCTs, 3867 patients) found that, compared to 
placebo or another inotrope, levosimendan decreased 
the risk of AKI [RR 0.79 (0.63–0.99)] and the need for 
RRT [RR 0.52 (0.32–0.86)]. When limiting the analysis 
to high-quality studies, the difference in need for RRT 
between groups failed to reach significance [RR 0.41 
(0.15–1.12)] [161]. Studies in both meta-analyses were 
small, there was some heterogeneity, AKI was not always 
a predefined endpoint, different definitions of AKI were 
used and there might have been some outcome report-
ing bias.
Three large placebo-controlled RCTs have recently 
been published. In patients with sepsis the use of levo-
simendan was not beneficial in terms of a reduction of 
renal SOFA, need for RRT [OR 0.99 (0.66–1.49)] or mor-
tality [OR 1.19 (0.82–1.72)], while its use was associated 
with more adverse events [162]. In 882 patients with left 
ventricular dysfunction undergoing cardiac surgery, lev-
osimendan had no effect on mortality or need for RRT 
[163]. No effect on AKI and RRT was seen when levosi-
mendan was given for haemodynamic support after car-
diac surgery in 506 patients [164] (ESM_2 Table S9).
Sedation
Recommendations
1. On the basis of current data no recommendation 
can be given, although it appears that shorter seda-
tion using propofol or dexmedetomidine may have 
several advantages, possibly reducing the rate of AKI 
(BPS).
Rationale
Sedation is necessary in many critically ill patients and 
this may affect cardiac function and/or vascular tone with 
renal consequences. In animal models propofol reduced 
markers of oxidative stress in the kidney [165, 166] and 
dexmedetomidine caused diuresis through reducing vas-
opressin secretion, enhancing renal blood flow and hence 
glomerular filtration [167] and showed renal protection 
[168–171].
Clinical studies
Propofol is commonly used as anaesthetic and for seda-
tion in the intensive care unit [172]. The “propofol infu-
sion syndrome” comprises myopathy, rhabdomyolysis, 
hyperkalaemia and AKI [173, 174]. On the basis of the 
data from case reports/series, it is recommended to 
administer propofol for a maximum of 48 h and a maxi-
mum dose of 4  mg/kg/h [175]. On the other hand, a 
recent propensity-matched cohort study in critically ill 
patients showed reduced risk of AKI and need for RRT 
in patients sedated with propofol as compared to mida-
zolam [176]. Furthermore a small RCT including 112 
patients undergoing valvular heart surgery showed less 
AKI and significantly lower cystatin C levels in the group 
treated with propofol as compared to sevoflurane [177]. 
However, the fact that remote ischaemic preconditioning 
showed less effect if patients were treated with propofol 
leaves uncertainty about the protective effect of propofol 
on the kidney [178].
α-2 Adrenergic agonists have multiple pharmacody-
namic effects [179]. In a placebo-controlled double-blind 
RCT dexmedetomidine demonstrated significant diu-
retic effects, with an almost 75% increase in diuresis after 
cardiac surgery, but did not affect renal function per se 
[180]. Observational trials indicated protection of kid-
ney function after cardiac surgery [181] but not when 
used for sedation during lung cancer resection [182]. A 
placebo-controlled study in 90 patients undergoing coro-
nary artery bypass graft (CABG) showed a dose-depend-
ent reduction of NGAL levels with dexmedetomidine 
used for postoperative sedation [183]. Another RCT in 
200 patients showed that dexmedetomidine for 24  h at 
0.4 μg/kg/h from start of anaesthesia resulted in reduced 
rate of AKI, morbidity and length of stay in the ICU [184] 
(ESM_2 Table S10).
Alltogether, the data for non-benzodiazepine seda-
tives, especially dexmedetomidine, are promising but 




1. We suggest targeting a blood glucose level at least 
below 180 mg/dL (10 mmol/l) for the prevention of 
hyperglycaemic kidney damage in the general ICU 
population (Grade 2B).
2. We suggest not using erythropoietin (Grade 2B) or 
steroids (Grade 2B) for prevention of acute kidney 
injury.
Rationale
In critical illness hyperglycaemia has been associated 
with adverse outcomes [185, 186] attributed to oxida-
tive stress, endothelial dysfunction, alterations in hae-
mostasis, immune dysregulation and mitochondrial 
dysfunction. The anti-inflammatory effect of steroids may 
attenuate the inflammatory component of AKI pathogen-
esis. Erythropoietin (EPO), besides being a haematopoi-
etic growth factor, also has tissue-protective properties 
by decreasing apoptosis and inflammation and by pro-
moting neovascularization and tissue regeneration.
Clinical studies
A large prospective RCT in 1548 surgical ICU patients 
compared tight glucose control (TGC) with insulin (target 
blood glucose 80–110  mg/dL) to standard care (insulin 
when blood glucose is greater than 200 mg/dL resulting 
in a mean blood glucose of 150–160 mg/dL) and showed 
not only an improved survival rate but also a 41% reduc-
tion in AKI requiring RRT [187]. Additionally, TGC also 
reduced the number of patients with peak plasma creati-
nine greater than 2.5 mg/dL by 27%. A subsequent study 
in the medical ICU of the same hospital, including many 
patients that already had AKI on admission, did not con-
firm the effect on survival or need for RRT, but showed 
a 34% reduction in AKI, defined as a doubling of serum 
creatinine compared with the admission level [188]. A 
combined analysis of both studies showed a more pro-
nounced renal protection when normoglycaemia was 
achieved [189].
More recent RCTs in septic [65] and general [190–194] 
ICU patients (some of which had to be stopped early 
because of hypoglycaemia) including a large adequately 
powered multicentre trial in Australia and New Zealand 
(NICE-SUGAR) [191] did not confirm the renoprotec-
tive effect. The latter even found a higher mortality in 
patients treated with TGC compared to an intermediate 
level. Clinicians should, however, be aware of important 
differences between these landmark trials, such as the 
glycaemic target in the control group, the nutritional 
strategy and the methods used to measure blood glucose 
levels [195]. The most recent meta-analysis on this issue 
did not find a mortality benefit [RR 1.06 (0.99–1.13)] 
[196] of TGC nor a renoprotective effect (evaluated 
by the need for RRT only) [RR 0.96 (0.83–1.11)] [196] 
(ESM_2 Table S11).
A major obstacle to the broad implementation of TGC 
is the increased risk of hypoglycaemia. Patients with AKI 
are at particular risk [197]. On the other hand, a causal 
relationship between a short-lasting iatrogenic hypo-
glycaemia in the monitored setting of an ICU and out-
come remains controversial [198–200]. If clinicians 
decide to adopt TGC strategies, fluctuations in glucose 
levels should be minimized and reliable tools should be 
employed to measure blood glucose [195]. Because of the 
risk of hypoglycemia, current guidelines suggest more 
moderate blood glucose targets (less than 180  mg/dL 
[20], less than 150 mg/dl [52], 140–180 mg/dL [201]) in 
critically ill patients, although these targets have not been 
formally compared with tolerating hyperglycaemia [202] 
(ESM_2 Table S11).
A recent large RCT (n =  4494) demonstrated no sig-
nificant effect of the intraoperative administration of 
dexamethasone on a composite endpoint of major com-
plications after cardiac surgery. The RR for RIFLE-Failure 
was 0.7 (0.44–1.14) [203]. A post hoc analysis of this trial 
showed a beneficial effect on the need for RRT (RR 0.44 
(0.19–0.96)), an effect that was mainly seen in patients 
with eGFR less than 15 ml/min/1.73 m2 and remains to 
be confirmed [204]. Another placebo-controlled RCT in 
7507 patients found no effect of methylprednisolone on 
the incidence of AKI stage 3 after cardiac surgery [205].
Prospective randomised placebo-controlled trials on 
the renoprotective effect of erythropoietin have mainly 
been performed in the setting of cardiac surgery [206–
210]. A recent meta-analysis (5 studies, 423 patients) 
found no effect of erythropoietin on the incidence of 
AKI: RR 0.64 (0.35–1.16). Surprisingly, a preplanned sub-
group analysis found a significant reduction of AKI in 
patients without high risk for AKI: RR 0.37 (0.24–0.61; 
p  <  0.0001) [211]. Similar results were obtained in the 
most recent meta-analysis, which in addition showed 
more protection with pre-anaesthetic administration 
[212]. Another RCT in cardiac surgery including 75 
patients with pre-existing renal impairment found no 
differences in postoperative levels of serum creatinine, 
cystatin C or NGAL [213]. A second meta-analysis (on a 
total of 2759 patients) that also included studies in ICU 
patients [214, 215] likewise did not establish a renopro-
tective effect of erythropoietin: incidence of AKI RR 0.72 
(0.79–1.19); dialysis requirement RR 0.72 (0.31–1.70), 
mortality RR 0.96 (0.78–1.18), all without significant 
heterogeneity amongst studies [216]. It should, however, 
be emphasized that in the largest study in ICU patients 
[215] AKI was only reported as an adverse effect and not 
clearly defined. Two more recent RCTs in the setting of 
thoracic aortic surgery [217] and contrast administration 
in diabetics [218] confirmed the absence of beneficial 
effect of EPO on the incidence of AKI or need for RRT in 
critically ill patients (ESM_2 Table S12).
Metabolic interventions
Recommendations
1. We recommend not using high-dose IV selenium for 
renal protection in critically ill patients (1B).
2. We suggest not using N-acetylcysteine to prevent 
contrast-associated AKI in critically ill patients 
because of conflicting results and possible adverse 
effects (Grade 2B).
3. We suggest that all patients with or at risk of acute 
kidney injury have adequate nutritional support pref-
erably through the enteral route (BPS).
Rationale
Starvation accelerates protein breakdown and impairs 
protein synthesis in the kidney, whereas feeding might 
exert the opposite effects and promote renal regen-
eration. In animal experiments increased protein intake 
has been shown to reduce tubular injury [219, 220], and 
enteral versus parenteral nutrition improved the reso-
lution of AKI [221]. On the other hand, amino acids 
infused before or during ischaemia may also enhance 
tubular damage and accelerate loss of renal function 
[222]. This may also extend to high-dose glutamine when 
given to patients during the injury phase of AKI [223]. 
Furthermore, brief periods of reduced food intake appear 
to increase resistance against ischaemia–reperfusion 
injury in rodents [224]. This “amino acid paradox” may 
be related to the increase in metabolic work for trans-
port processes which may aggravate ischaemic injury. 
Enhanced autophagy, induced by nutrient deprivation 
and promoting the repair of cellular damage, may be an 
alternative explanation. In this context permissive under-
feeding during the acute phase of critical illness may be 
protective against AKI.
One aspect of nutrition is the adequate supply of nutri-
tional co-factors and antioxidants such as the glutathione 
precursor N-acetylcysteine (NAC), antioxidant vitamins 
(vitamin E (α-tocopherol) and vitamin C (ascorbic acid)) 
as well as selenium. However, these antioxidants have 
also been investigated in pharmacological doses with the 
intention to provide protection against damage by oxy-
gen radicals.
Clinical studies
Protein(s) and amino acids augment renal perfusion and 
improve renal function, representing recruitment of 
“renal reserve capacity” [225]. An RCT investigating the 
effects of daily intravenous amino acid supplementation 
up to 100  g/day in 424 critically ill patients could not 
find a significant effect on the duration of AKI despite 
an increase in eGFR in the treatment group [226]. Fur-
thermore, there was a trend towards increased need for 
RRT which corresponds to findings from the EPaNIC 
trial where early parenteral nutrition increased the 
duration of RRT probably driven by higher urea levels 
[227]. Correspondingly, lower caloric intake (defined 
as receiving less than 60% of requirements, also called 
permissive underfeeding) has been found to be associ-
ated with a lower risk for RRT (RR 0.711, 95% CI 0.545–
0.928) [228].
A host of RCTs have been performed comparing NAC 
to placebo or other interventions with or without hydra-
tion in non-critically ill patients receiving radiocontrast 
media [229–237]. Results are controversial as alluded 
to earlier but the latest meta-analysis assessing the effi-
cacy of intravenous NAC only showed no reduction of 
AKI or RRT [238]. The ACT trial, currently the largest 
RCT including 2308 patients undergoing coronary and 
peripheral vascular angiography, failed to demonstrate 
any beneficial effect of NAC [239]. RCTs in the critically 
ill population are not available.
RCTs examining the role of NAC in the prevention 
of renal dysfunction in high-risk contexts like car-
diac surgery showed controversial results [240–246] 
(ESM_2 Table S13). In addition IV NAC may be harm-
ful leading to allergic reactions [247] and decreased 
cardiac output or survival in patients with septic shock 
[248, 249].
A small RCT in 42 patients showed that selenium sup-
plementation decreased the requirement for RRT from 
43% to 14% in patients with SIRS [250]. These finding 
could, however, not be reproduced in consecutive trials 
[251] including two larger RCTs involving 249 and 1089 
patients with sepsis [252, 253].
Statins
Recommendations
1. We recommend against the perioperative use of high-
dose statins to prevent postoperative AKI in cardiac 
surgery (Grade 1A).
2. We suggest the short-term use of atorvastatin or 
rosuvastatin to prevent contrast-associated AKI in 
high-risk patients undergoing coronary contrast 
angiography (Grade 2B).
Rationale
The pleiotropic effect of statins, including antioxidant, 
anti-inflammatory and antithrombotic effects, may con-
tribute to nephroprotection [254].
Clinical studies
Statins may have a beneficial role in high-risk patients 
exposed to contrast administration for angiography, as 
suggested by three recent RCTs [255–257]. In a mul-
ticentre trial in China, 2998 patients with type 2 diabe-
tes or mild to moderate CKD undergoing coronary or 
peripheral arterial angiography were randomised to a 
5-day course of rosuvastatin versus no statin [255]. The 
incidence of CA-AKI was significantly lower in those 
receiving rosuvastatin (2.3% vs. 3.9%, respectively, 
p = 0.01). In a single-centre study [256], 504 statin-naïve 
patients with acute coronary syndrome (ACS) scheduled 
to undergo an early invasive strategy were randomised 
to high-dose rosuvastatin at the time of admission ver-
sus treatment with atorvastatin commenced at hospital 
discharge; 6.7% of patients in the early high-dose statin 
group developed CA-AKI compared to 15.1% in the con-
trol group. The 30-day rate of adverse cardiovascular and 
renal events was also significantly reduced in the rosu-
vastatin group (3.6% vs. 7.9%, respectively, p  =  0.036). 
An RCT in 410 CKD patients showed less CA-AKI in 
patients randomised to a single dose of atorvastatin 
within 24  h before contrast exposure compared to the 
control group (4.5% vs. 17.8%, p  =  0.005) [257]. Two 
more recent RCTs found similar effects of statins in dia-
betics with CKD [258, 259]. These positive findings were 
confirmed by several meta-analyses combining studies 
in patients undergoing coronary angiography [260–263] 
(ESM_2 Table  S14). One of these meta-analyses con-
cluded that short-term, pre-procedural, intensive statin 
treatment only reduced CA-AKI in ACS patients and 
recommended further studies in non-ACS patients [264]. 
This meta-analysis, however, did not include the largest 
RCT [255]. Although, these results lend support to the 
short-term use of statins before procedures involving 
intra-arterial contrast exposure in patients with coronary 
artery disease with or without diabetes and/or CKD, it 
must be considered that most of the studies were per-
formed outside the ICU, thereby warranting downgrad-
ing of the level of evidence.
In patients undergoing cardiac surgery, two large 
meta-analyses including data from observational studies 
found conflicting evidence regarding the role of preop-
eratve statin in preventing postoperative AKI [265, 266], 
and a Cochrane analysis of small RCTs found no effect 
[267]. Two recent placebo-controlled RCTs investigated 
the effects of perioperative high-dose atorvastatin (i.e. 
80 mg, followed by 40 mg daily) in elective cardiac sur-
gery [268] and valvular heart surgery [269] and showed 
no renal benefit. Furthermore, in the largest trial, 
statin-naïve patients with CKD had a higher incidence of 
AKI when treated with statin [268] (ESM_2 Table S15). 
Finally, an even larger placebo-controlled RCT in 1922 
cardiac surgery patients that included AKI as a second-
ary outcome demonstrated renal harm in those receiv-




1. We suggest not using remote ischaemic precondi-
tioning for prevention of AKI in critically ill patients 
(Grade 2A).
Rationale
Remote ischaemic preconditioning (RIPC) or several 
short cycles of limb ischaemia is achieved through infla-
tion of a blood pressure cuff. The mechanism by which 
RIPC prevents AKI is incompletely understood.
Clinical studies
In cardiac surgery several single-centre RCTs demon-
strated reduced incidence of AKI and need for RRT 
[271–273]. However, several others, including four larger 
and multicentric RCTs [274–277] did not confirm these 
beneficial effects, nor was a change in creatinine or 
mortality demonstrated. The conflicting results in car-
diac surgery may be explained by inclusion of low-risk 
patients in trials that showed no benefit, and the use of 
propofol and opioids, treatments that may blunt the ben-
eficial effects of RIPC.
In 13 recent meta-analyses the effect of RIPC was eval-
uated in different cohorts and definitions of AKI [178, 
278–289]. Though several meta-analyses found a reduc-
tion of AKI [278, 279, 281–284, 286, 287, 289, 290] this 
was restricted to stage 1 AKI [289], or subgroups such as 
percutaneous coronary interventions [278, 279], or car-
diac surgery with propofol-free anaesthesia [283]. The 
meta-analyses are limited by risk of bias, heterogeneity 
in definitions of AKI, low event rates and underestima-
tion of influence of co-morbidities [283, 289]. Finally, a 
Cochrane review including studies on patients undergo-
ing surgery could not show a benefit on renal outcomes 
[178] (ESM_2 Table S16).
In summary, the effects by which RIPC prevents AKI 
are incompletely understood. RIPC for prevention of AKI 
has mainly been evaluated in cardiovascular surgery and 
after contrast administration. Larger studies and meta-
analyses are not consistent in demonstrating a preventive 
effect of RIPC for AKI.
AKI care bundles
Recommendations
1. We suggest using the KDIGO recommendations to 
reduce the incidence of AKI after cardiac surgery 
(Grade 2C).
2. The use of AKI care bundles outside the intensive 
care unit has some benefits, including the potential 
to improve the outcome of AKI (BPS).
Rationale
Care bundles have been proposed as tools to improve 
the quality of care and outcome of patients with AKI. 
Ideally, they should contain a small set of practices, pro-
cesses or treatments that are evidence-based, endorsed 
and/or recommended by guidelines and broadly 
accepted as appropriate and/or standard care by local 
stakeholders. They are designed such that if one ele-
ment is not implemented, the remaining elements are 
not impacted.
Clinical studies
Outside the critical care setting, different AKI care bun-
dles have been implemented with variable improvement 
in clinical care, more efficient resource use and potentially 
improved outcomes, especially if combined with educa-
tional measures and electronic alerting [291–293]. To date, 
care bundles comprising the KDIGO recommendations 
have only been investigated in one study including 274 car-
diac surgery patients at high risk for AKI as determined by 
AKI biomarkers. The study showed less postoperative AKI 
(although mainly by the urine output criteria) without, 
however, influencing any major patient-centred outcome 
like RRT or renal recovery at day 30 [294]. The treatment 
strategy included avoidance of nephrotoxins and hypergly-
caemia as well as applying goal-directed haemodynamic 
optimisation. It is unclear which element was effective 
because goal-directed therapy (GDT) neither prevented 
AKI nor reduced the need for RRT in septic shock, as 
shown by a secondary analysis [23] and a meta-analysis of 
three recent large RCTs [295], but avoiding nephrotoxins, 
hyperglycaemia and hypovolaemia seems to be reasonable.
Conclusions and summary
Prompt resuscitation of the circulation with fluids, vaso-
pressors and inotropes remains the cornerstone in the 
prevention of AKI. Volume expansion with isotonic 
crystalloids is only recommended in states of true and 
suspected hypovolaemia. Uncontrolled volume expan-
sion and the use of starches and dextrans should be 
avoided. Following or together with fluid resuscitation 
hypotensive patients should be given a vasoconstric-
tor, preferably norepinephrine, and titrated individually 
with a target MAP of 65–70  mmHg being adequate in 
most individuals without pre-existing chronic hyperten-
sion. The potential role of vasopressin requires further 
investigation. Together with these measures a review of 
all medications with the cessation of those known to be 
nephrotoxic is mandatory. Diuretics should not be used 
for prevention of AKI alone but may benefit the kidney by 
relieving renal congestion. Frank hyperglycaemia should 
be avoided. The effect of statins appears to depend on the 
setting, with promising results in contrast administra-
tion but no effect or even harm in cardiac surgery. There 
is low-level evidence that the choice of the sedative may 
impact kidney function. The conflicting results on ischae-
mic preconditioning preclude a firm recommendation.
Heterogeneous definitions of AKI still hamper compari-
son of different studies, despite the commendable efforts 
by the ADQI, AKIN and KDIGO working groups [2, 296, 
297]. In addition, AKI is frequently reported as a secondary 
outcome. Although several RCTs have fuelled the literature 
on prevention of AKI over the past 4–5 years, the available 
evidence remains insufficient. Many recommendations are 
therefore formulated as weak with low grade quality of evi-
dence. More high-quality studies with consensus AKI defi-
nitions will be required to fill the knowledge gaps.
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